Related Experiment Videos
[A 45-fold liraglutide overdose did not cause hypoglycaemia]
Lene Ring Madsen1, Jens Juel Christiansen
1Medicinsk Endokrinologisk Afdeling, Aarhus Universitetshospital, Nørrebrogade 44, 8000 Aarhus C. leemas@rm.dk.
Ugeskrift for Laeger
|February 5, 2015
Summary
Glucagon-like peptide-1 (GLP-1) analogue liraglutide overdose did not cause hypoglycemia. This case study highlights the drug's safety profile, even in extreme overdose scenarios, with only mild gastrointestinal symptoms observed.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 (GLP-1) analogues are increasingly used for type 2 diabetes management.
- Liraglutide mimics native GLP-1 actions: enhancing insulin secretion, suppressing glucagon, increasing satiety, and slowing gastric emptying.
Observation:
- A patient intentionally overdosed on liraglutide, taking 45 times the prescribed amount.
- Plasma liraglutide levels confirmed the significant overdose.
Findings:
- Despite the massive overdose, the patient experienced only nausea and vomiting.
- Crucially, no hypoglycemia or signs of pancreatitis were observed.
Implications:
- This case suggests a wide safety margin for liraglutide, even in extreme overdose situations.
- The findings support the understanding that GLP-1 receptor agonists may have a low risk of inducing hypoglycemia.
- Further research into the safety profile of GLP-1 analogues in overdose is warranted.